Pacific Point Advisors LLC Makes New Investment in Zoetis Inc. (NYSE:ZTS)

Pacific Point Advisors LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,100 shares of the company's stock, valued at approximately $878,000.

Other large investors also recently bought and sold shares of the company. Mission Wealth Management LP raised its stake in shares of Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after buying an additional 59 shares during the period. VeraBank N.A. raised its stake in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after buying an additional 62 shares during the period. HUB Investment Partners LLC raised its stake in shares of Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after buying an additional 62 shares during the period. Coppell Advisory Solutions LLC raised its stake in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after buying an additional 64 shares during the period. Finally, Deseret Mutual Benefit Administrators raised its stake in shares of Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock worth $170,000 after buying an additional 65 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research reports. Piper Sandler boosted their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. UBS Group dropped their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Finally, Stifel Nicolaus dropped their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $212.75.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares of the company's stock, valued at $1,868,244.30. The trade was a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is currently owned by insiders.

Zoetis Stock Performance

ZTS traded up $3.65 on Tuesday, hitting $166.23. 2,322,895 shares of the company traded hands, compared to its average volume of 3,051,614. The company has a 50 day moving average of $156.47 and a 200-day moving average of $164.68. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The stock has a market capitalization of $74.01 billion, a PE ratio of 30.39, a PEG ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the previous year, the business earned $1.38 earnings per share. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.20%. Zoetis's dividend payout ratio is presently 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.